Key Points
- Robert Gould sold 15,000 shares of Fulcrum Therapeutics on Nov. 19 at an average price of $11.03 for $165,450, reducing his stake by 3.00% to 484,864 shares (≈$5.35M) according to an SEC filing.
- Shares traded up ~2.1% to $11.29 on Friday with a market cap of about $611M and a 52-week range of $2.32–$12.19, after the company reported a quarterly EPS of ($0.31), missing estimates.
- Analyst coverage is mixed (average rating "Moderate Buy" and $13 target), while institutional investors hold roughly 89.83% of the stock.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) Director Robert Gould sold 15,000 shares of Fulcrum Therapeutics stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $11.03, for a total value of $165,450.00. Following the sale, the director owned 484,864 shares of the company's stock, valued at approximately $5,348,049.92. This trade represents a 3.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Fulcrum Therapeutics Trading Up 2.1%
Shares of NASDAQ FULC traded up $0.23 during mid-day trading on Friday, reaching $11.29. The company had a trading volume of 431,992 shares, compared to its average volume of 945,636. The stock has a market cap of $611.01 million, a price-to-earnings ratio of -9.57 and a beta of 3.02. Fulcrum Therapeutics, Inc. has a 52 week low of $2.32 and a 52 week high of $12.19. The business's 50-day moving average is $8.86 and its 200-day moving average is $7.56.
Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its quarterly earnings data on Wednesday, October 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.02). As a group, equities research analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current year.
Hedge Funds Weigh In On Fulcrum Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of FULC. Quarry LP purchased a new stake in shares of Fulcrum Therapeutics during the 3rd quarter valued at $35,000. Farther Finance Advisors LLC increased its position in Fulcrum Therapeutics by 108.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company's stock valued at $65,000 after buying an additional 3,697 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Fulcrum Therapeutics by 4,209.3% in the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company's stock valued at $64,000 after buying an additional 9,092 shares during the last quarter. Assetmark Inc. acquired a new stake in Fulcrum Therapeutics in the third quarter worth about $88,000. Finally, Jump Financial LLC acquired a new stake in Fulcrum Therapeutics in the first quarter worth about $30,000. 89.83% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on FULC. Wall Street Zen cut shares of Fulcrum Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, November 1st. HC Wainwright restated a "buy" rating and set a $12.00 target price on shares of Fulcrum Therapeutics in a report on Monday, October 20th. Piper Sandler reaffirmed an "overweight" rating and set a $16.00 target price (up previously from $12.50) on shares of Fulcrum Therapeutics in a research report on Thursday, October 30th. Leerink Partners set a $20.00 price target on Fulcrum Therapeutics and gave the company an "outperform" rating in a report on Tuesday, October 21st. Finally, Royal Bank Of Canada upped their price objective on Fulcrum Therapeutics from $5.00 to $7.00 and gave the stock a "sector perform" rating in a research note on Thursday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $13.00.
View Our Latest Stock Report on Fulcrum Therapeutics
About Fulcrum Therapeutics
(
Get Free Report)
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
